Last updated: 2026-09-16 09:04:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Seaport Therapeutics, Inc. (SPTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23.08, with a market capitalisation of $1.32B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.85 to $28.38. This page covers its latest market performance, valuation, price trends and company information.
$1.32B | |
$24.56 | |
$28.38 | |
$14.85 | |
$24.70 | |
138.54K | |
166.95K | |
-- | |
$28.38 | |
$14.85 | |
-- | |
-- |
Seaport Therapeutics, Inc. (SPTX) is trading at $24.75 in pre-market trading as of 2026-09-15 23:31:00, up 0.18% ($0.05) from the previous close of $24.70
Pre-market trading shows how investors are pricing SPTX before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Seaport Therapeutics, Inc. (SPTX) moved from $24.86 to $23.08, representing a decline of 7.16% ($1.78).
The stock traded between $21.58 and $25.52 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 167.84 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 60.8%
SPTX is currently trading at $23.08, placing it 60.8% of the way from its 52-week low of $14.85 to its 52-week high of $28.38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Seaport Therapeutics, Inc. (SPTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.